Clinical Nurse Specialist Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Kimberly Rohan

Clinical Nurse Specialist, Oncology Naperville, IL Clinical Nurse Specialist

NPI 1982749750 CMS profile 10767875

120 Spalding Dr, Suite 111, Naperville, IL 60540

Open in the dashboard

General payments

$192,181

386 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Kimberly Rohan of Naperville, IL is reported in the CMS Open Payments database as having received $192,181 across 386 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 98th percentile of Clinical Nurse Specialist, Oncology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $33,357 54
2024 General $29,385 48
2023 General $58,791 102
2022 General $42,917 108
2021 General $27,732 74

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Kimberly Rohan
  • Clinical Nurse Specialist, Oncology median
  • Middle half of Clinical Nurse Specialist, Oncology
  • National median

In program year 2025, general payments to Kimberly Rohan were reported at $33,357. Among 100 Clinical Nurse Specialist, Oncology profiles paid that year, the median was $250 and the middle half received between $100 and $1,290.

Show as a table
Year Kimberly Rohan Clinical Nurse Specialist, Oncology median Middle half National median
2019 $0 — — $163
2020 $0 — — $114
2021 $27,732 $260 $105–$604 $132
2022 $42,917 $157 $99–$880 $149
2023 $58,791 $244 $95–$808 $160
2024 $29,385 $319 $137–$1,282 $164
2025 $33,357 $250 $100–$1,290 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AstraZeneca Pharmaceuticals LP $77,285 99 payments
  2. Regeneron Healthcare Solutions, Inc. $73,033 135 payments
  3. Genzyme Corporation $16,836 28 payments
  4. Takeda Pharmaceuticals U.S.A., Inc. $6,135 10 payments
  5. G1 Therapeutics, Inc. $4,914 9 payments
  6. Pharmacosmos Therapeutics Inc. $4,360 7 payments
  7. Genentech USA, Inc. $3,065 13 payments
  8. Epizyme, Inc., $1,899 7 payments
  9. Seattle Genetics, Inc. $814 5 payments
  10. Janssen Scientific Affairs, LLC $680 1 payment
  11. Other $3,160 72 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $135,890 92 payments
  2. Travel and Lodging $29,084 111 payments
  3. Consulting Fee $10,891 11 payments
  4. Food and Beverage $8,899 152 payments
  5. Honoraria $5,419 6 payments
  6. Education $1,248 13 payments
  7. Compensation for serving as faculty or as a speaker for a medical education program $750 1 payment
Products named General payments · program years 2021–2025
  1. LIBTAYO $89,711 159 payments
  2. TAGRISSO $39,710 45 payments
  3. IMFINZI $21,389 33 payments
  4. COSELA Oncology $4,874 7 payments
  5. COSELA Hematology $4,360 7 payments
  6. TAZVERIK $1,899 7 payments
  7. EXKIVITY $1,705 2 payments
  8. TECENTRIQ $1,141 6 payments
  9. Alecensa $1,050 1 payment
  10. PADCEV $772 1 payment
  11. Other $3,511 95 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

386 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Clinical Nurse Specialist, Oncology in Illinois

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record